171 related articles for article (PubMed ID: 26364709)
1. Nanoparticle agglomerates of indomethacin: The role of poloxamers and matrix former on their dissolution and aerosolisation efficiency.
Malamatari M; Somavarapu S; Bloxham M; Buckton G
Int J Pharm; 2015 Nov; 495(1):516-526. PubMed ID: 26364709
[TBL] [Abstract][Full Text] [Related]
2. Intact nanoparticulate indomethacin in fast-dissolving carrier particles by combined wet milling and aerosol flow reactor methods.
Laaksonen T; Liu P; Rahikkala A; Peltonen L; Kauppinen EI; Hirvonen J; Järvinen K; Raula J
Pharm Res; 2011 Oct; 28(10):2403-11. PubMed ID: 21537875
[TBL] [Abstract][Full Text] [Related]
3. Nanosuspensions of poorly soluble drugs: preparation and development by wet milling.
Liu P; Rong X; Laru J; van Veen B; Kiesvaara J; Hirvonen J; Laaksonen T; Peltonen L
Int J Pharm; 2011 Jun; 411(1-2):215-22. PubMed ID: 21458552
[TBL] [Abstract][Full Text] [Related]
4. Effect of a melt agglomeration process on agglomerates containing solid dispersions.
Vilhelmsen T; Eliasen H; Schaefer T
Int J Pharm; 2005 Oct; 303(1-2):132-42. PubMed ID: 16139973
[TBL] [Abstract][Full Text] [Related]
5. Study on Enhanced Dissolution of Azilsartan-Loaded Solid Dispersion, Prepared by Combining Wet Milling and Spray-Drying Technologies.
Lu T; Sun Y; Ding D; Zhang Q; Fan R; He Z; Wang J
AAPS PharmSciTech; 2017 Feb; 18(2):473-480. PubMed ID: 27116201
[TBL] [Abstract][Full Text] [Related]
6. Nano-scale and molecular-level understanding of wet-milled indomethacin/poloxamer 407 nanosuspension with TEM, suspended-state NMR, and Raman measurements.
Kuroiwa Y; Higashi K; Ueda K; Yamamoto K; Moribe K
Int J Pharm; 2018 Feb; 537(1-2):30-39. PubMed ID: 29246438
[TBL] [Abstract][Full Text] [Related]
7. Formulation strategy and evaluation of nanocrystal piroxicam orally disintegrating tablets manufacturing by freeze-drying.
Lai F; Pini E; Corrias F; Perricci J; Manconi M; Fadda AM; Sinico C
Int J Pharm; 2014 Jun; 467(1-2):27-33. PubMed ID: 24680963
[TBL] [Abstract][Full Text] [Related]
8. Spray drying of drug-swellable dispersant suspensions for preparation of fast-dissolving, high drug-loaded, surfactant-free nanocomposites.
Azad M; Arteaga C; Abdelmalek B; Davé R; Bilgili E
Drug Dev Ind Pharm; 2015; 41(10):1617-31. PubMed ID: 25347144
[TBL] [Abstract][Full Text] [Related]
9. Development of novel polymer-stabilized diosmin nanosuspensions: in vitro appraisal and ex vivo permeation.
Freag MS; Elnaggar YS; Abdallah OY
Int J Pharm; 2013 Sep; 454(1):462-71. PubMed ID: 23830765
[TBL] [Abstract][Full Text] [Related]
10. Solid dispersions of itraconazole for inhalation with enhanced dissolution, solubility and dispersion properties.
Duret C; Wauthoz N; Sebti T; Vanderbist F; Amighi K
Int J Pharm; 2012 May; 428(1-2):103-13. PubMed ID: 22414388
[TBL] [Abstract][Full Text] [Related]
11. Dissolution study of nanocrystal powders of a poorly soluble drug by UV imaging and channel flow methods.
Sarnes A; Østergaard J; Jensen SS; Aaltonen J; Rantanen J; Hirvonen J; Peltonen L
Eur J Pharm Sci; 2013 Nov; 50(3-4):511-9. PubMed ID: 23999036
[TBL] [Abstract][Full Text] [Related]
12. Preparation of amorphous indomethacin nanoparticles by aqueous wet bead milling and in situ measurement of their increased saturation solubility.
Colombo M; Minussi C; Orthmann S; Staufenbiel S; Bodmeier R
Eur J Pharm Biopharm; 2018 Apr; 125():159-168. PubMed ID: 29371046
[TBL] [Abstract][Full Text] [Related]
13. Application of the combinative particle size reduction technology H 42 to produce fast dissolving glibenclamide tablets.
Salazar J; Müller RH; Möschwitzer JP
Eur J Pharm Sci; 2013 Jul; 49(4):565-77. PubMed ID: 23587645
[TBL] [Abstract][Full Text] [Related]
14. Drying of crystalline drug nanosuspensions-the importance of surface hydrophobicity on dissolution behavior upon redispersion.
Van Eerdenbrugh B; Froyen L; Van Humbeeck J; Martens JA; Augustijns P; Van den Mooter G
Eur J Pharm Sci; 2008 Sep; 35(1-2):127-35. PubMed ID: 18644441
[TBL] [Abstract][Full Text] [Related]
15. Spray drying of API nanosuspensions: Importance of drying temperature, type and content of matrix former and particle size for successful formulation and process development.
Czyz S; Wewers M; Finke JH; Kwade A; van Eerdenbrugh B; Juhnke M; Bunjes H
Eur J Pharm Biopharm; 2020 Jul; 152():63-71. PubMed ID: 32376369
[TBL] [Abstract][Full Text] [Related]
16. Formulation, optimization and in vitro-in vivo evaluation of febuxostat nanosuspension.
Ahuja BK; Jena SK; Paidi SK; Bagri S; Suresh S
Int J Pharm; 2015 Jan; 478(2):540-52. PubMed ID: 25490182
[TBL] [Abstract][Full Text] [Related]
17. Edge activators and a polycationic polymer enhance the formulation of porous voriconazole nanoagglomerate for the use as a dry powder inhaler.
Salem HF; Kharshoum RM; Abdel Hakim LF; Abdelrahim ME
J Liposome Res; 2016 Dec; 26(4):324-35. PubMed ID: 26872552
[TBL] [Abstract][Full Text] [Related]
18. Dissolution rate enhancement and physicochemical characterization of carbamazepine-poloxamer solid dispersions.
Medarević DP; Kachrimanis K; Mitrić M; Djuriš J; Djurić Z; Ibrić S
Pharm Dev Technol; 2016; 21(3):268-76. PubMed ID: 25582577
[TBL] [Abstract][Full Text] [Related]
19. Fabrication of drug-loaded edible carrier substrates from nanosuspensions by flexographic printing.
Palo M; Kolakovic R; Laaksonen T; Määttänen A; Genina N; Salonen J; Peltonen J; Sandler N
Int J Pharm; 2015 Oct; 494(2):603-610. PubMed ID: 25601198
[TBL] [Abstract][Full Text] [Related]
20. Spray granulation: importance of process parameters on in vitro and in vivo behavior of dried nanosuspensions.
Figueroa CE; Bose S
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1046-55. PubMed ID: 23916460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
